Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/73307
Título: | Economic evaluation of a multimodal intervention in pre-frail and frail older people with diabetes mellitus: the MID-FRAIL project | Autores/as: | Peña-Longobardo, Luz María Oliva-Moreno, Juan Zozaya González, Mª Neboa Aranda-Reneo, Isaac Trapero Bertran,Marta Laosa, Olga Sinclair, Alan Rodríguez-Mañas, Leocadio |
Clasificación UNESCO: | 32 Ciencias médicas | Palabras clave: | Cost-Utility Diabetes Economic Evaluation Frailty Health Care Costs, et al. |
Fecha de publicación: | 2021 | Publicación seriada: | Expert Review of Pharmacoeconomics and Outcomes Research | Resumen: | Background: The aim of this study was to estimate the incremental cost-utility ratio (ICUR) of a multi-modal intervention in frail and pre-frail subjects aged ≥70 years with type-2 diabetes versus usual care group focused on quality adjusted life years (QALYs) in different European countries. Methods: The MID-FRAIL study was a cluster randomized multicentre trial conducted in seven European countries. A cost-utility analysis was carried out based on this study, conducted from the perspective of the health care system with a time horizon of one year. Univariate and probabilistic analysis were carried out to test the robustness of the results. Results: The cost estimation showed the offsetting health effect of the intervention program on total health care costs. The mean annual health care costs were 25% higher among patients in usual care. The mean incremental QALY gained per patient by the intervention group were 0.053 QALY compared with usual care practice. Conclusions: The MID-FRAIL intervention program showed to be the dominant option in comparison with usual care practice. It saved costs to the health care system and achieved worthwhile health gains. This finding should encourage its implementation, at least, in the trial participant countries. | URI: | http://hdl.handle.net/10553/73307 | ISSN: | 1473-7167 | DOI: | 10.1080/14737167.2020.1766970 | Fuente: | Expert Review of Pharmacoeconomics and Outcomes Research [ISSN 1473-7167], v. 21(1), p. 111-118 |
Colección: | Artículos |
Citas SCOPUSTM
8
actualizado el 08-sep-2024
Citas de WEB OF SCIENCETM
Citations
9
actualizado el 08-sep-2024
Visitas
105
actualizado el 06-jul-2024
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.